Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed)
ID: 344212Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $350K

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/344212

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-032.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity aimed at the late-stage translation of biomedical and behavioral research results related to arthritis and musculoskeletal diseases into the marketplace. This initiative, categorized under the Small Business Innovation Research (SBIR) grants (R43/R44), seeks to support small business concerns (SBCs) in collaboration with academic and non-profit labs to expedite the development and commercialization of diagnostic tools, therapies, and preventive measures, while specifically excluding clinical trials. The program emphasizes the importance of partnerships between technology developers and SBCs, requiring applicants to demonstrate their ability to advance projects with defined milestones and clear commercialization plans, with funding amounts up to $350,000 for Phase I and $2 million for Phase II grants. Interested applicants should note that the application deadline is September 5, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-032-Full-Announcement.html
    PAR-23-032.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), announces a funding opportunity focused on the late-stage translation of biomedical and behavioral research results related to arthritis and musculoskeletal diseases into the marketplace. This opportunity, categorized under Small Business Innovation Research (SBIR) grants (R43/R44), aims to support small business concerns (SBCs) that foster collaboration with academic and non-profit labs to expedite the development and commercialization of diagnostic tools, therapies, and preventive measures. The solicitation emphasizes the necessity for close partnerships between original technology developers and SBCs, promoting late-stage pre-clinical studies that set the groundwork for regulatory approval of new technologies, while excluding clinical trials. Eligible applicants must demonstrate their capability to advance projects with defined milestones and clear commercialization plans. Key application details include budget limitations of up to $300,000 for Phase I and $2 million for Phase II grants, with specific submission deadlines outlined for different cycles. Additionally, applicants must adhere to stringent eligibility criteria and application guidance to ensure compliance and timely review. This initiative underscores NIH's ongoing commitment to advancing healthcare innovations through strategic funding and collaboration, enhancing public health outcomes through technological advancement.
    Similar Opportunities
    Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Required) to support early-career scientists transitioning into entrepreneurial roles within small businesses. This funding opportunity aims to facilitate the career development of investigators by providing entrepreneurial training, mentorship, and support for research and development projects that align with NIH's mission to improve health. Eligible small business concerns (SBCs) can apply for Phase I and Fast-Track grants, with funding amounts typically reaching $306,872 for Phase I and $2,045,816 for Phase II awards. Applications will be accepted starting August 5, 2024, with a closing date of April 5, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-134.html.
    NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for small business concerns (SBCs) through the NINDS Exploratory Clinical Trials program (R43/R44), aimed at supporting investigator-initiated exploratory clinical trials related to neurological disorders. This program invites applications for studies that evaluate drugs, biologics, devices, or therapies, generating preliminary data to inform future clinical development, with a focus on enhancing diverse perspectives within research teams. Eligible U.S.-based SBCs can apply for funding caps of up to $295,924 for Phase I and $1,972,828 for Phase II, with applications due by September 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-311.html.
    Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering Exploratory Clinical Trial Grants (R61) to support research in arthritis and musculoskeletal and skin diseases. This funding opportunity aims to facilitate short-term, interventional studies that address critical research questions, particularly those evaluating drug efficacy in rare diseases, without requiring preliminary data. Grants can provide up to $600,000 over three years, with applications due by November 2, 2026. Interested applicants are encouraged to consult with NIH staff during the application process and can find additional information at NIH Grants or by contacting NIH Grants Information at grantsinfo@nih.gov.
    Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering funding opportunities through the "Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases" program, specifically under the R61 Clinical Trial mechanism. This initiative aims to support short-term exploratory clinical trials that investigate treatments for rheumatic, musculoskeletal, and skin conditions, with a focus on diverse therapeutic approaches. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and state and local governments, with a maximum budget of $600,000 for a three-year project, not exceeding $300,000 in any single year. Applications must be submitted electronically via Grants.gov, with key deadlines starting from February 4, 2024, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov. For more details, visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-035.html.
    Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Not Allowed) to support early-career scientists transitioning into entrepreneurship. This funding opportunity aims to facilitate the development of promising technologies by small business concerns (SBCs) while providing mentorship and entrepreneurial training for Program Directors/Principal Investigators (PDs/PIs) who are new to research entrepreneurship. The initiative is designed to enhance the biomedical workforce by coupling scientific expertise with essential business skills, ultimately contributing to public health advancements. Applications are invited for SBIR Phase I and Fast-Track grants, with deadlines ranging from September 2024 to April 2027. For more information, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-131.html.
    NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre-Clinical Research (R44 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) to support pre-clinical research aimed at bridging funding gaps that impede the commercialization of medical biotechnology products. This funding opportunity specifically targets previously funded SBIR or STTR Phase II projects, with the objective of advancing products or technologies that require federal regulatory approval, while fostering partnerships between small businesses and external investors to enhance commercialization prospects. Applicants are encouraged to secure independent third-party funding that equals or exceeds one-third of the requested NINDS funds, and must include a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity in the research environment. The application deadline is April 5, 2027, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found in the full announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-222.html.
    NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)" aimed at supporting Small Business Concerns (SBCs) in conducting investigator-initiated exploratory clinical trials related to neurological disorders. This initiative encourages applications for Phase I and II studies focusing on drugs, biologics, devices, and therapies that align with the mission of the National Institute of Neurological Disorders and Stroke (NINDS), emphasizing the inclusion of a Plan for Enhancing Diverse Perspectives (PEDP) to foster innovation. The maximum funding amounts are $295,924 for Phase I and $1,972,828 for Phase II projects, with applications required to demonstrate readiness for eventual FDA regulatory approval. Interested applicants can begin submitting proposals on December 5, 2023, with the application deadline set for September 5, 2026; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), in collaboration with the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA), has announced the PHS 2024-2 Omnibus Solicitation for Small Business Innovation Research (SBIR) Grant Applications. This funding opportunity invites eligible U.S. small businesses to submit applications for Phase I, Phase II, Fast-Track, and Direct to Phase II projects that align with the research missions of the NIH, CDC, and FDA, with a focus on stimulating technological innovation and commercialization of federal R&D investments. Notably, applications must not include clinical trials, and funding levels are capped at $306,872 for Phase I and up to $2,045,816 for Phase II, with a submission deadline of April 5, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the "Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Required)" to support early-career scientists transitioning into entrepreneurship. This funding opportunity aims to facilitate the career development of investigators by providing grants that support research and development activities, alongside essential entrepreneurial training and mentorship. The program is specifically designed for U.S. small business concerns, with a focus on fostering innovation and enhancing public health, particularly from diverse and historically underrepresented groups. Interested applicants must submit their proposals by April 5, 2027, and can find additional information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the "Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed)" to support early-career scientists in their transition to entrepreneurship. This grant aims to facilitate the development of small business concerns (SBCs) by employing researchers as Program Directors/Principal Investigators (PDs/PIs), providing them with essential entrepreneurial training, mentorship, and a structured framework for developing commercially viable biomedical technologies. The program is particularly focused on enhancing the entrepreneurial skills of scientists with strong technical expertise but limited experience in entrepreneurship, thereby aligning with NIH's mission to improve health. Interested applicants must be U.S.-based small businesses, and the application process will commence in September 2024, with a closing date of April 5, 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-133.html.